


IN THE CLAIMS

1. (original): A compound of the formula



(I)

or a pharmaceutically acceptable salt thereof.

2. (currently amended): A pharmaceutical composition for treating a disorder or condition selected from Alzheimer's disease, Crutzfeld Jacob's disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, Down's syndrome, pancreatitis, inclusion body myositis, other peripheral amyloidoses and diabetes in a mammal, including a human, comprising an amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

3. (currently amended): A method of treating a disorder or condition selected from Alzheimer's Disease, Crutzfeld Jacob's disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, Down's syndrome, pancreatitis, inclusion body myositis, other peripheral amyloidoses and diabetes in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating Alzheimer's Disease, such disorder or condition.

4 (withdrawn): A method according to claim 3, wherein the disorder or condition being treated is Alzheimer's disease.

5.(withdrawn): A method according to claim 3, wherein the disorder or condition being treated is Down's syndrome.

6.(withdrawn): A method according to claim 3, wherein the disorder or condition being treated is amyotrophic lateral sclerosis.

7.(withdrawn) A method according to claim 3, wherein the disorder or condition being treated is stroke.

8.(withdrawn) A method according to claim 3, wherein the disorder or condition being treated is head trauma.

9.(withdrawn) A method according to claim 3, wherein the disorder or condition being treated is a diabetes.

10.(withdrawn): A method according to claim 3, wherein the disorder or condition being treated is pancreatitis.

11.(withdrawn); A method according to claim 3, wherein the disorder or condition being treated is inclusion body myocitis.

12.(withdrawn): A method according to claim 3, wherein the disorder or condition being treated is a prion disorder.

13. (withdrawn): A method according to claim 3, wherein the disorder or condition being treated is Crutzfeld-Jacob's disease.

14. (withdrawn) A method according to claim 3, wherein the disorder or condition being treated is progressive supranuclear palsy.

15.(withdrawn): A method according to claim 3, wherein the disorder or condition being treated is selected from vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson's disease, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Crutzfeld-Jacob's disease, substance-induced persisting dementia, dementia due to multiple etiologies, and dementia not otherwise specified (NOS), or the disorder or condition is a dementia of the Alzheimer's type and is selected from the group consisting of dementia of the Alzheimer's type with early onset uncomplicated, dementia of the Alzheimer's type with early onset with delusions, dementia of the Alzheimer's type with early onset with depressed mood, dementia of the Alzheimer's type with late onset uncomplicated, dementia of the Alzheimer's type with late onset with delusions and dementia of the Alzheimer's type with late onset with depressed mood.

16. (new): A method of treating a condition in which inhibition of beta-secretase is indicated comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1.

17. (new): The method of claim 16 wherein said condition is Alzheimer's Disease.